A Double-masked, Randomized Study to Investigate the Safety and Efficacy of Daclizumab to Treat the Ocular Complications Related to Behçet's Disease

Ronald R. Buggage Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, MD, USA

Grace Levy-Clarke Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, MD, USA

Hatice N. Sen Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, MD, USA

Roxana Ursea Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, MD, USA

Sunil K. Srivastava Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, MD, USA

Eric B. Suhler Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, MD, USA

Chandra Altemare Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, MD, USA

Gisela Velez Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, MD, USA

Jack Ragheb Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, MD, USA

Chi-Chao Chan Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, MD, USA

Robert B. Nussenblatt Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, MD, USA

Alison T. Bamji National Eye Institute, National Institutes of Health, Bethesda, MD, USA

Puspha Sran National Eye Institute, National Institutes of Health, Bethesda, MD, USA

Thomas Waldmann Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

Darby J. S. Thompson The EMMES Corporation, Rockville, MD, USA

REFERENCES